Skip to content
- PDSB: A New Board as PDS Biotech Prepares Its Next Cancer-Trial Push
- DFSC: From Army Demonstrations to Commercial Orders—DEFSEC’s Next Test
- XHLD: TEN Holdings Takes Its Digital-Experience Platform to Investors
- ESLA: Two Infusions, One Patient—and a Bigger Cancer-Therapy Question
- AMOD: Bitcoin Riches Meet the Per-Share Value Test
- AHT: A $17 Million Fee Waiver Changes Ashford’s Liquidity Story
- INVE: A $20 Million Tender Offer Puts a Price on Shareholder Returns
- OLOX: From Natural Gas to Computing Power—The Execution Test Begins
- HOST: A Buyback Headline Lifts the AI Data-Center Story—Now Comes the Funding Test
- PRSO: A $2 Million Wireless Order Gives Peraso’s Rally a Concrete Catalyst
